Morphic Holding Investor Relations Material
Latest events
Study Update
Morphic Holding
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Morphic Holding Inc
Access all reports
Morphic Holding Inc., a biopharmaceutical company, specializes in the discovery and development of oral small-molecule integrin therapeutics. These treatments are aimed at addressing a variety of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. A key focus of their research is on MORF-057, an α4β7 integrin inhibitor designed to modulate inflammation, currently in clinical trials for treating inflammatory bowel disease. Morphic's pipeline also explores integrin targets for other gastrointestinal indications, myelofibrosis, and solid tumors among others. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Key slides for Morphic Holding Inc
Corporate Presentation
Morphic Holding Inc
Corporate Presentation
Morphic Holding Inc
Latest articles
Burberry: From WWI Trench Coats to Global Luxury
Explore Burberry's journey from a small outfitter to a global luxury fashion icon under Daniel Lee's creative vision.
17 May 2024
Phil Knight: The Entrepreneurial Genius Behind Nike
The life, work, and legacy of Nike’s legendary founder Phil Knight and his path to the top of athletic footwear and apparel.
16 May 2024
Palantir Technologies and Its Broad Spectrum of Impact
Discover how Palantir Technologies, a leader in data analytics since 2003, shapes global events and keeps growing rapidly into various domains.
16 May 2024
Ticker symbol
Country
🇺🇸 United States